Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Margetuximab - MacroGenics

Drug Profile

Margetuximab - MacroGenics

Alternative Names: Anti-HER2-monoclonal-antibody-Green-Cross; MARGENZA; Margetuximab-cmkb; MGAH-22

Latest Information Update: 28 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Raven biotechnologies
  • Developer GC Biopharma; Green Cross; MacroGenics; Merck Sharp & Dohme; ZAI Lab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II/III Gastric cancer; Oesophageal cancer
  • No development reported Haematological malignancies; Solid tumours
  • Discontinued Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 24 Feb 2022 The National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for HER2-positive breast cancer in China in January 2022
  • 24 Feb 2022 Zai Lab discontinues enrolment in the phase II/III MAHOGANY trial for Gastric cancer and Oesophageal cancer (Metastatic disease, Late-stage disease, First line therapy, Combination therapy) in China (IV) in February 2022 (NCT04082364)
  • 16 Feb 2022 Efficacy and safety data of the final overall survival (OS) analysis from a phase III SOPHIA trial in Brest cancer presented at 44th Annual San Antonio Breast Cancer Symposium (SABCS-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top